SCHEMBL3580912

SCHEMBL3580912

C#Cc1ccc2cccc(CNC(=O)N3CCC[C@H]3C(=O)NCCOC)c2c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.46
FKBP1A P62942 1/20 0.43
CFD P00746 1/20 0.43
KLK7 P49862 1/20 0.43
NQO2 P16083 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
MTNR1A P48039 4/20 0.42
MTNR1B P49286 3/20 0.42
ALDH1A1 P00352 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
P2RX7 Q99572 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
PKM P14618 1/20 0.42
CYP2C19 P33261 1/20 0.42
EPHX2 P34913 1/20 0.42
TACR1 P25103 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3576203 0.88 POLB (0.46) POLBFKBP1ACFDKLK7MEN1
SCHEMBL3576515 0.87 MEN1 (0.55) POLBFKBP1ANQO2L3MBTL1MEN1
SCHEMBL3575490 0.87 POLB (0.45) POLBFKBP1AMEN1KMT2AALDH1A1
SCHEMBL3574501 0.85 POLB (0.48) POLBFKBP1ANQO2MEN1KMT2A
SCHEMBL3574503 0.85 POLB (0.48) POLBFKBP1ANQO2MEN1KMT2A
SCHEMBL3579602 0.85 POLB (0.49) POLBFKBP1AMEN1KMT2AALDH1A1
SCHEMBL3579936 0.84 POLB (0.45) POLBFKBP1ACFDKLK7MEN1
SCHEMBL3578218 0.83 POLB (0.54) POLBFKBP1AMEN1KMT2AALDH1A1
SCHEMBL3585964 0.83 POLB (0.47) POLBNQO2MEN1KMT2AALDH1A1
SCHEMBL3574125 0.83 POLB (0.47) POLBFKBP1AMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130028843-A1 KALLIKREIN 7 MODULATORS NOVARTIS AG (CH) 2013-01-31 US disclosed
US-8309596-B2 Kallikrein 7 modulators NOVARTIS AG (CH) 2012-11-13 US disclosed
US-20100256144-A1 Kallikrein 7 modulators NOVARTIS AG (CH) 2010-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130028843-A1 KALLIKREIN 7 MODULATORS KLK7, KLK5, KLKB1 POLB 4716/4885FKBP1A 2112/4885CFD 335/4885
US-20100256144-A1 Kallikrein 7 modulators KLK7, KLK5, KLKB1 POLB 4716/4885FKBP1A 2112/4885CFD 335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.